TABLE 3.
In vitro susceptibilities of BSIs of Candida spp. tested to fluconazole and itraconazole
| Species | No. of isolates | Antifungal agent | MIC (μg/ml)
|
% Ra | ||
|---|---|---|---|---|---|---|
| Range | 50% | 90% | ||||
| C. albicans | 163 | Fluconazole | 0.12–>128 | 0.25 | 1.0 | 0.6 |
| Itraconazole | 0.015–>8.0 | 0.06 | 0.12 | 0.6 | ||
| C. glabrata | 46 | Fluconazole | 1.0–>128 | 8.0 | 32 | 8.7 |
| Itraconazole | 0.12–>8.0 | 0.5 | 2.0 | 36.9 | ||
| C. parapsilosis | 48 | Fluconazole | 0.12–4.0 | 1.0 | 2.0 | 0 |
| Itraconazole | 0.015–0.5 | 0.12 | 0.25 | 0 | ||
| C. tropicalis | 24 | Fluconazole | 0.25–4.0 | 0.5 | 2.0 | 0 |
| Itraconazole | 0.03–1.0 | 0.12 | 0.5 | 4.2 | ||
| C. krusei | 6 | Fluconazole | 32–64 | 32 | 100b | |
| Itraconazole | 0.12–2.0 | 1.0 | 66.6 | |||
| Candida spp.c | 19 | Fluconazole | 0.25–16 | 2.0 | 16 | 0 |
| Itraconazole | 0.03–2.0 | 0.25 | 1.0 | 15.8 | ||
a
% R, percent resistant by using interpretive breakpoint criteria of the NCCLS (5): fluconazole resistance, ≥64 μg/ml; itraconazole resistance, ≥1.0 μg/ml.
b
Isolates of C. krusei are considered resistant to fluconazole, irrespective of the MIC.
c
Includes C. guilliermondii (2 isolates) and Candida spp. (17 isolates).